Bahcesehir University
Istanbul, 34053, Turkey (Türkiye)
Location status: Recruiting
NCT Number: NCT07348926
This study aims to examine the psychological status and quality of life of families with children who have rare genetic disorders. The focus of the study is to understand how the child's level of functional independence relates to the well-being of the family. Functional independence will be assessed using standardized tools, and parental psychological status and quality of life will be evaluated with validated questionnaires.
The information gathered from this study may help improve the understanding of how rare genetic disorders affect family dynamics and daily functioning. The results may guide health care professionals in planning family-centered physiotherapy, psychological support, and care programs.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
Istanbul, 34053, Turkey (Türkiye)
Location status: Recruiting
This observational, descriptive, and cross-sectional study aims to examine the associations between the functional independence levels of young children diagnosed with rare genetic disorders and various psychosocial outcomes of their caregivers, including depression, family functioning, sleep quality, and overall quality of life. Rare genetic disorders often begin in early childhood, require long-term medical follow-up and rehabilitation, and may negatively affect both the daily routines and psychosocial well-being of families. In this context, understanding family-centered physiotherapy and its role as a protective factor is crucial for strengthening family systems and supporting rehabilitation success.
The study population consists of caregivers of children aged 0-4 years with rare genetic diagnoses who are receiving physiotherapy at a rehabilitation center in Istanbul. A sample size of 45 participants was calculated based on Cohen's effect size approach, assuming a medium effect size (d = 0.5).
Functional independence of the child will be assessed using the Pediatric Functional Independence Measure (WeeFIM). Based on WeeFIM scores, parents will be categorized into two groups according to the child's functional level. Caregiver depression levels will be assessed using the Beck Depression Inventory; family functioning will be evaluated with the Family Functionality in Rehabilitation Scale; family impact will be measured with the Family Impact Scale; sleep quality will be evaluated using the Pittsburgh Sleep Quality Index; and quality of life will be assessed using the Nottingham Health Profile. Demographic information and details of physiotherapy participation will also be collected.
Data collection will begin after ethical approval and will last approximately three months. Following informed consent, all participants will complete the questionnaires in Turkish. The findings of this study are expected to provide a comprehensive understanding of the multidimensional challenges faced by families of children with rare genetic disorders and may guide the development of family-centered physiotherapy, psychosocial interventions, and supportive care programs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline (study enrollment)
The functional independence level of children with rare genetic disorders will be assessed using the Pediatric Functional Independence Measure (WeeFIM). This scale evaluates functional abilities in self-care, mobility, and cognition. Higher scores indicate greater functional independence.
Time frame: At baseline (study enrollment)
Caregiver depressive symptoms will be assessed using the Beck Depression Inventory (BDI). This scale measures emotional, cognitive, and physical symptoms of depression. Higher scores indicate higher levels of depressive symptoms.eck Depression Inventory (BDI), higher scores indicate greater severity of depressive symptoms.
Time frame: At baseline (study enrollment)
This outcome will assess the caregiver's perceived role and functionality in the child's rehabilitation process using the Family Functionality in Rehabilitation Scale. Higher scores indicate better family functioning within the rehabilitation setting.
Time frame: At baseline (study enrollment)
The Family Impact Scale will be used to evaluate how the child's rare genetic condition affects family routines, emotional well-being, and daily functioning. Higher scores indicate greater perceived impact on family life.
Time frame: At baseline (study enrollment)
Caregiver sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI), which evaluates sleep duration, latency, disturbances, and overall sleep quality. Higher scores reflect poorer sleep quality.
Time frame: At baseline (study enrollment)
Caregiver quality of life will be assessed using the Nottingham Health Profile (NHP), which evaluates emotional, social, and physical domains of well-being. Higher scores indicate poorer quality of life.
Contact information is provided by the study sponsor or research team.
Tuğçe Tahmaz, PhD
CONTACT
Yağmur Erkan, PT
CONTACT
Bahçeşehir University
Other
Examination of Families' Psychological Status and Quality of Life According to the Functional Independence Status of Children With Rare Genetic Diseases in Early Childhood
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07039084
Augmentative and Alternative Communication, Behavior
Melbourne, Victoria, Australia
View Trial DetailsNCT06326905
Behavior, Behavioral Symptoms
Baltimore, Maryland, United States
View Trial DetailsNCT05563805
Anxiety, Anxiety Disorders
Arlington, Texas, United States
View Trial DetailsNCT05810259
Anxiety, Anxiety Disorders
New Haven, Connecticut, United States
View Trial Details